Compare Boston Scientific Corporation (BSX) vs Altria Group Inc (MO) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

Altria Group (MO) trades at $68.35, up 0.89% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains strong profitability with 39% net income margin and $6.95B net income for 2025, though revenue declined slightly to $20.14B. Recent earnings show alternating beats and misses, with Q3 2026 results pending. Analyst consensus remains bullish with 61.5% buy ratings and $71.50 price target, while the stock offers a 6.3% dividend yield with 56 consecutive annual increases expected.

MO presents value opportunity with 14.4x P/E ratio and strong cash flow generation, but faces headwinds from cigarette volume declines and regulatory pressures. The smoke-free product transition shows progress but remains early stage. Current price near support at $67 suggests limited downside, while analyst targets indicate 4.6% upside potential. Key risks include litigation exposure and slower-than-expected diversification from traditional tobacco products.